FDA Grants Approval for Clinical Data, Inc.’s (CLDA) Viibryd
Today, Clinical Data, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets to be marketed under the brand name Viibryd™. A new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A receptor partial agonist, Viibryd will be used to treat adults with major depressive disorder (MDD). The company plans to make Viibryd available in U.S. pharmacies before June 30th of this year. “When treating MDD, our goal is to offer treatment options that meet the individual needs of each patient,” stated Stephen M. Stahl, M.D., Ph.D., Professor of Psychiatry, University…